CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
REQUIT aims to develop validated clinical models and biomarkers to predict side-effects in cancer patients undergoing radiotherapy. By identifying high-risk individuals before treatment, the project seeks to design interventional trials that improve quality of life for cancer survivors.
Long-term side-effects of radiotherapy impact on the quality-of-life (QoL) of cancer survivors.
These side-effects could be reduced if predicted in advance.
Previous work identified clinical and biological predictors but a major, coordinated approach is needed to validate them so they can be used clinically.
The EU has ~17.8 million people living with a prior diagnosis of cancer of whom ~7 million received radiotherapy.
In the long-term, potentially 20% of those suffering with mild to severe sid…
THE UNIVERSITY OF MANCHESTER
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
France, MONTPELLIER
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
Germany, Heidelberg
Type: Research institute
Activity type: Research Organisations
SME: No
Belgium, Gent
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
United Kingdom, Leicester
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 sectors.
